Creative Medical Technology Holdings Announces IMMCELZ™ Adoptive Immunotherapy Product

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"Clinical Stage Adult Stem Cell Therapy Company Discovers New Way to Stop Immune Diseases without Immune Suppression\n\n\nPHOENIX, March 11, 2020 /PRNewswire/ -- Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named \"IMMCELZ™\".\n\n \n \n \n \n \n \n\n \nUtilizing the newly discovered properties of regenerative cells to alter immune cells, the Company has found a new method of developing \"patient-specific\" treatments for diseases in which the immune system pathologically starts to attack healthy tissues in the body, a state termed \"autoimmunity\".\nThe autoimmune disease market is estimated to be approximately $38 billion annually1. Common autoimmune diseases include Type 1 diabetes, Rheumatoid arthritis, Psoriasis/Psoriatic arthritis, Multiple sclerosis, Systemic lupus erythematous (lupus), Inflammatory bowel diseases, Myasthenia gravis, Vasculitis, Celiac disease and Hashimoto's Thyroiditis.\n\"Current drugs treating autoimmunity act to suppress the immune system globally, thus increasing the risks of infections and cancers,\" said Dr. Thomas Ichim, Chief Scientific Officer of the Company and Co-Inventor of the technology. \"In contrast, the IMMCELZ™ product specifically reprograms cells of the immune system in order to specifically stop attack against the body's own tissues, while preserving immune responses against cancer and infectious diseases.\"\nIMMCELZ™, which is protected by trade secrets and published US patent application 15/987739, utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. After the patient immune cells are incubated with the donor stem cells, the immune cells are extracted and re-injected back into the patient. These \"reprogrammed cells\" subsequent \"educate\" other cells of the immune system to stop attacking the body, while preserving ability to attack cancers and foreign pathogens.\n\"While the results are preliminary, and additional research is needed before clinical trials may begin, we believe that the current interest in cellular immunotherapy, will turn in using these types of approaches for treatment of autoimmunity,\" said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. \"Examples of...

More updates from Creative Medical Technology Holdings, Inc.